Bem-vindo ao blog do Laboratório de Bioinformática Estrutural (LaBiE) da ULBRA

Laboratório vinculado ao Curso de Química e ao Programa de Pós-Graduação em Genética e Toxicologia Aplicada (PPGGTA) da Universidade Luterana do Brasil (Ulbra)
Localização:
Av. Farroupilha, 8001 - Prédio 01, Sala 122 - Bairro São José, Canoas/RS
CEP: 92425-900 - Tel: +55(51)34774000 ext 2774

terça-feira, 22 de março de 2011

Curso de Bioinformática aplicado em genoma, metagenoma e transcriptoma

O LNCC (Laboratório Nacional de Computação Científica ) em conjunto com o CBAB (Centro Brasileiro-Argentino de Biotecnologia) estão oferecendo o curso "Ferramentas de bioinformática aplicadas à análise de sequências genômicas, metagenômicas e transcriptômicas"

Este curso será realizado entre os dias 4 a 15 de julho de 2011.

Novo biofármaco pode aprimorar o tratamento do diabetes

Um medicamento elaborado na UFRJ com recursos da nanobiotecnologia pode ajudar a tornar o tratamento para o diabetes mais eficaz.

Um biofármaco que acaba de ser desenvolvido por pesquisadores da Universidade Federal do Rio de Janeiro (UFRJ) - e que já teve seu pedido de patente depositado no Instituto Nacional da Propriedade Industrial (INPI) - pode representar um novo caminho para tornar o tratamento do diabetes mais eficaz. O medicamento, produzido no Laboratório de Biotecnologia Farmacêutica da universidade (BiotecFar), é baseado em um sistema de liberação prolongada de amilina humana e tem como objetivo oferecer aos diabéticos um melhor controle da glicemia.

Trocando em miúdos, a amilina é um hormônio produzido naturalmente no pâncreas (pelas células beta), que desempenha um papel fundamental em diversos órgãos, inclusive para equilibrar os níveis de glicose. Este hormônio é cosecretado com a insulina, exercendo conjuntamente papéis importantes na regulação metabólica. "Mesmo pacientes diabéticos que fazem uso da insulina possuem dificuldades de controle dos níveis de glicose no sangue", explica o professor da UFRJ Luís Maurício Lima, coordenador do projeto que teve início em 2009.

Atualmente, o tratamento para diabetes leva em conta apenas a reposição de insulina, deixando de lado a reposição da amilina. Isso ocorre devido à dificuldade de desenvolver medicamentos a base de amilina humana, que é bastante insolúvel. "Ao contrário da insulina, que é livremente solúvel, a amilina humana tem um problema de agregação protéica, que inclusive é causa de diabetes amiloidogênica e ainda a razão da dificuldade de usar o hormônio natural terapeuticamente", afirma o farmacêutico.

Para contornar esse obstáculo e desenvolver o novo medicamento, os pesquisadores do BiotecFar/UFRJ recorreram a um minucioso trabalho de nanobiotecnologia farmacêutica. No laboratório, eles encapsularam nanopartículas de amilina humana em partículas poliméricas biocompatíveis. Por serem tão pequenas, elas podem ser facilmente administradas por injeção subcutânea ou intramuscular e por terem como base polímeros biocompatíveis são naturalmente degradadas e eliminadas pelo organismos. Apesar de continuarem insolúveis, formam um depósito que vai se degradando aos poucos no local de aplicação. "Produzimos nanopartículas contendo amilina humana de 200 nanômetros, que é uma medida equivalente a cerca de um milionésimo de metro", conta Lima.

Uma vantagem do uso de nanopartículas é a liberação contínua e lenta da amilina humana. Esta característica permite que as aplicações de amilina humana, sejam por injeções intramuscular ou subcutânea, não precisem ser diárias. "Esse detalhe é importante para manter a qualidade de vida do paciente diabético que já recebe doses diárias de insulina. Assim, o paciente não precisaria receber mais injeções diárias, de análogos solúveis de amilina, o que tornaria o tratamento mais desconfortável e menos próximo ao fisiológico por não se tratar da amilina humana. Podemos programar aplicações semanais ou até mensais", destaca o professor. "A ideia é que a reposição de amilina humana seja um tratamento complementar à reposição de insulina, para potencializar o controle da glicemia", completa.

Leia a matéria completa no site: www.faperj.br.

(Agência Faperj)

Structural biology: Breaking the protein rules

If dogma dictates that proteins need a structure to function, then why do so many of them live in a state of disorder?

Keith Dunker's life is a mess. His desk is so swamped with books, old chocolate bars, half-reviewed manuscripts, pens, coke bottles and — somewhere — a stray sock, that he ends up printing papers again rather than wading in to find the original. "I'm so disorganized," he crows, "some people have called me Dr Disorder." But he remembers with great precision the moment that disorder invaded his scientific life. It was 15 November 1995, at 12:40 p.m., halfway through a seminar by crystallographer Chuck Kissinger, at Washington State University in Pullman, where Dunker was then a biochemist. Dunker was staring at a slide showing the atomic structure of calcineurin, an enzyme targeted by immunosuppressive drugs. What caught his attention wasn't the intricate structure but something missing from it: a dotted line representing a string of amino acids with a position too variable to be determined by X-ray crystallography, as the rest of the protein had been. And Kissinger was insisting that this loop had to remain flexible for calcineurin to serve its crucial function in the human immune system.

"It hit me like a brick," says Dunker: this wayward piece of protein flouted a century of dogma. A central tenet in molecular biology is that the function of a protein depends critically on its fixed three-dimensional structure; by extension, enzymes bind to specific substrates because their shapes match perfectly, as immortalized in the 'lock-and-key' model proposed by chemist Emil Fischer as early as 1894. But this part of calcineurin seemed to disobey these rules, by providing function without structure. Now Dunker was wondering how many other proteins were ignoring the rules too.

To find out, he and his colleagues wrote a bioinformatics program that predicted which protein segments are 'intrinsically disordered' — meaning that they do not fold spontaneously into a unique three-dimensional shape. Today, this and other similar programs predict that about 40% of all human proteins contain at least one intrinsically disordered segment of 30 amino acids or more, and that some 25% are likely to be disordered from beginning to end1. This part of the protein universe had largely been ignored because disordered protein segments impede crystal formation — a prerequisite for X-ray diffraction, the predominant way structures are deduced — and structural biologists clip them out whenever they can.

Today, though, "the recognition of disorder has grown dramatically", Peter Wright, a protein biophysicist at the Scripps Research Institute in La Jolla, California, told the American Association for the Advancement of Science meeting in Washington DC last month. A large part of that recognition has come from studies using nuclear magnetic resonance (NMR) spectroscopy, which allows researchers to determine the structures of small proteins even as they twist and turn in solution. Such work has shown that disorder can actually be essential to function by helping a signalling protein to recognize and react to a protein partner, or by allowing a regulatory protein to interact with multiple targets. Still, says Wright, "that hasn't got through to the textbooks".

Many structural biologists see no need for revision. "My mantra has been: function requires structure," declares Tom Steitz, a crystallographer at Yale University in New Haven, Connecticut. "Some flexibility can be required, it may be an essential part of the assembly process, but it's not interesting until the proteins get to do their job." Critics argue that the computer programs predicting high levels of disorder are fundamentally flawed because they identify proteins that are well-known to become perfectly ordered — and to crystallize — when bound to their proper molecular partners. They say that unfolded protein chains cannot persist for long in living cells, and some want the concept of intrinsically disordered proteins to be ditched altogether. That seems unlikely. Data are fast accumulating from all fronts — biophysics, bioinformatics and cell biology — in support of widespread disorder, and disorder aficionados are calling for a complete reassessment of the structure–function paradigm. "Biology uses disorder to bring about its various functions," Wright says.

Since the late 1950s, newly made proteins have been assumed to fold up immediately and spontaneously into a unique three-dimensional shape — their most energetically stable conformation and the only functional one2. The few proteins known to remain unfolded "were pointed to as oddities", Wright says. But that started to change in 1999, when Wright and fellow NMR spectroscopist Jane Dyson, also at Scripps, wrote a review3 pointing to the growing collection of proteins that seemed to function despite their disordered state. It has been "the big-dog paper in the field", says Dunker, now at Indiana University School of Medicine in Indianapolis.

One burning question, then and now, is how a protein can function if it has no fixed shape. "We all accept flexibility," says structural biologist Joël Janin at the CNRS Laboratory of Enzymology and Structural Biochemistry at Gif-sur-Yvette, France. "The question is: how can you get recognition with flexibility?" The whole concept of disorder seems incompatible with the lock-and-key model. You might as well try to open the door with cooked spaghetti.

In 2007, postdoc Kenji Sugase in Wright's lab found an answer: the spaghetti uses the lock to mould itself into the shape of the key, rather than forming the key beforehand. Sugase focused on CREB, a gene-regulatory protein involved in many processes including learning and memory. Once bound to DNA, CREB also needs to recognize and bind a protein partner called CBP before it can switch on the gene. But the part of CREB involved with CBP enters the game in a disordered state. How could a thing like this possibly work?

To find out, Sugase developed the equivalent of a super-fast NMR camera so that he could capture frequent snapshots of CREB's wriggling chain, at atomic resolution, as it tested out points of contact within itself and with CBP. What he saw was that several bonds had to form cooperatively within CREB and with CBP for the whole complex to snap into shape4. That's exactly how the average 'globular' protein folds: its internal segments need to establish long-range chemical bonds with one another, to pull the whole thing suddenly into shape2. CREB forms such interactions externally, by bonding to CBP — and if this bonding is just a little weaker, then the key cannot form and there is no binding with the lock at all. Wright and his colleagues think that disorder is therefore advantageous because it allows CREB to partner with CBP more exclusively than a rigid protein would. And Wright thinks that this type of process allows many signalling proteins to engage in speedy yet selective interactions.

Disorderly conduct

The structure–function mantra took an even bigger hit recently from a protein with parts that never seem to fold at all. The Sic1 signalling protein is a key regulator of the cell cycle that puts the brakes on DNA replication until the cell is ready to divide. In 2001, a team led by Mike Tyers, a yeast cell-cycle expert at the University of Toronto, Canada, began unpicking the mechanism of the switch. The group found that when phosphate groups are added to six sites on Sic1 it can then hook up with a second protein, Cdc4, which pushes Sic1 into the cell's protein-disposal pathways5. Once Sic1 is degraded, DNA replication can forge ahead. But unless that degradation occurs at precisely the right time, DNA replication goes haywire and the cell may eventually die. The cell achieves that precision by ensuring that it takes exactly six phosphates to flip the switch, not four or five. But there's a rub: Cdc4 has only one high-affinity binding pocket for a phosphate group. How can Cdc4 'count' up to six with effectively only one finger to count on?

Tumour-supressor protein p53 contains an ordered, globular domain (brown); its disordered segments (colours) help it interact with hundreds of partners.Click for larger version.

After all attempts to crystallize the Sic1 complex failed, Tyers's team called NMR spectroscopist Julie Forman-Kay, also at the University of Toronto. In 2008, Tanja Mittag, a postdoc in Forman-Kay's lab, showed that Sic1 was disordered6 — not only in its free state but, astoundingly, also when bound to Cdc4. The complex seemed to be a mixture of different conformations shifting around in constant, dynamic equilibrium. And the most stunning part was that each of the six phosphate groups on Sic1 could be found to occupy the single Cdc4 pocket, one after the other, as in a constant dance around the fire (see 'Orders of disorder').

The researchers then developed a computer model and fed it with every scrap of experimental data about the proteins' structures that they could gather7. They concluded that, even though Sic1 is disordered when it is bound, it maintains a rather compact structure, which keeps all the phosphate groups sufficiently close together to form an average electrostatic field that glues Sic1 to Cdc4. Only when six phosphates are present is the glue strong enough for Cdc4 to hold Sic1 close and force-feed it into the cell's disposal machinery. And one reason that Sic1 has to be disordered during all this, the team proposes, is to enable the rather rigid disposal machinery to reach all parts of Sic1 and carpet it with the chemical tags that mark the protein for destruction. It takes a nimble protein indeed to make all these connections at once.

"The result is interesting," says structural biologist Stephen Harrison of Harvard Medical School in Boston, "because interaction motifs are often found more or less repeated along unstructured segments, and the work shows how such multiplicity can function." And Forman-Kay thinks that adopting 'multi-structural' states could allow other proteins to constantly probe and sense signals from many partners at once. This is particularly important for 'hub' proteins, which are central to vast networks of rapidly changing molecular interactions. "There is a complexity people haven't talked about," she says. "These hub proteins need to very rapidly sample the complex cellular environment."

Tumour-supressor protein p53 contains an ordered, globular domain (brown); its disordered segments (colours) help it interact with hundreds of partners.M. BLACKLEDGE/IBS GRENOBLE

One extreme example can be seen in the tumour suppressor p53, an extraordinarily well connected hub in multiple signalling networks, and the protein most frequently implicated in human cancer. Part of the explanation for p53's promiscuity seems to lie in its versatile structure, which features every possible conformation from order to disorder. The core domain is globular and binds to DNA and just a few other proteins; its two flanking wings are mostly disordered and can bind to hundreds of signalling partners; and a segment within one wing shows a 'chameleon' status which can flip between four different ordered states, depending on which partner it binds to8. Alan Fersht, a biophysicist and NMR expert at the University of Cambridge, UK, says that he is "absolutely sure" that long parts of p53 remain largely disordered in the cell: "I don't think there's any doubt about that whatsoever."

Prediction problems

Yet many researchers question how widespread disordered proteins can be. That is mainly because biochemists, over more than 100 years of preparing tissue extracts, have struggled to prevent proteins from unfolding and tangling into insoluble clumps or getting digested by enzymes called proteases. "It's hard to believe that disordered proteins could produce anything else than a mess," says Janin.

Researchers who study these processes, however, say that such fears are largely irrelevant. In human cells, for example, nonspecific proteases are locked away in compartments called lysosomes, which should allow disordered proteins to survive everywhere else, explains Ulrich Hartl, an expert on protein quality control at the Max Planck Institute in Martinsried, Germany. Disordered proteins should also be protected from aggregation because, unlike globular proteins, they contain few hydrophobic amino acids, which tend to stick together — and are instead rich in 'polar' amino acids that are happy swimming in water.

Hartl thinks that natural selection against aggregation probably gave disordered proteins this particular amino-acid composition — in other words, it is not a signature for disorder per se. And this explains an apparent inconsistency of disorder predictors: that they do not pick internal segments from globular proteins, even though these too are incapable of folding on their own when sliced out of a protein2. The reason is that they are rich in hydrophobic amino acids and so do not show the signature sequence that the predictors detect. It also explains why the predictors select some proteins that are in fact ordered, another point of controversy surrounding these programs: because proteins can lack hydrophobic amino acids for reasons other than disorder. "This makes perfectly good sense," agrees Dunker.

Overall, the numerous programs claim an 80% success rate at predicting whether any individual amino acid in a protein will be surrounded by order or disorder1, as compared to the 50% success rate expected by chance — and crystallographers rely on them to sideline proteins expected to resist crystallization. "Disorder predictors are a massive oversimplification, but they are very useful," says Adam Godzik, at the Burnham Institute in La Jolla, California, and head of the bioinformatics group for the Protein Structure Initiative, a large collaboration that aims to solve large numbers of protein structures.

Nevertheless, debate about the prevalence and importance of disorder has probably slowed progress in the field. DisProt, a database of proteins whose disorder has been established experimentally, contains just over 500 proteins, a number dwarfed by the more than 60,000 structures in the Protein Data Bank1, the database for 3D structures. "The main reason why DisProt is so small," says Dunker, "is because it has taken so many damn years to get it funded." But in the past few years, major consortia aimed at exploring intrinsically disordered proteins have been set up in several countries. Interest in disordered proteins as drug targets is also on the rise because so many of them, like p53, are crucially implicated in disease.

ADVERTISEMENT

Click here

Little by little, a fundamentally new picture of the relationships between protein sequence, structure and function is emerging: a continuum running from the most rigid 'lock-and-key' enzymes and molecular machines at one extreme through to durably unstructured spaghetti such as Sic1 at the other, and spanning all degrees of structural ambiguity in between. Figuring out how all these disordered proteins really work is a long way off, if Sic1 is anything to go by: determining its mode of action involved several, often arcane, biophysical techniques, new computer tools and statistical physics theory — plus at least ten years of work by six labs. Multi-structural biology isn't going to be simple.

Still, Dunker, Wright and other doctors of disorder are optimistic. As is Martin Blackledge, an NMR spectroscopist at the Institute of Structural Biology in Grenoble, France, who compares the excitement now to that surrounding the first crystal protein structures in the 1950s. "Every new case is fascinating at the moment," he says. Blackledge looks forward to a day when it might be possible to predict where on the structural continuum a protein segment falls, from its amino-acid sequence — to crack the full code of disorder. "This is exactly what I'm aiming for," he says, "this is my dream."

Perhaps the rules of disorder are needed, before disorder can rule.

Tanguy Chouard is an editor for Nature in London.

  • References

    1. Uversky, V. N. & Dunker, A. K. Biochim. Biophys. Acta 1804, 1231-1264 (2010).
    2. Anfinsen, C. B. Science 181, 223-230 (1973). | Article | PubMed | ISI | ChemPort |
    3. Wright, P. E. & Dyson, H. J. J. Mol. Biol. 293, 321-331 (1999). | Article | PubMed | ISI | ChemPort |
    4. Sugase, K., Dyson, H. J. & Wright P. E. Nature 447, 1021-1025 (2007). | Article | PubMed | ChemPort |
    5. Nash, P. et al. Nature 414, 514-521 (2001). | Article | PubMed | ISI | ChemPort |
    6. Mittag, T. et al. Proc. Natl Acad. Sci. USA 105, 17772-17777 (2008).
    7. Mittag, T. et al. Structure 18, 494-506 (2010).
    8. Oldfield, C. J. et al. BMC Genomics 9 (Suppl. 1), S1 (2008).